What is Akermin?
Headquartered at the prestigious BRDG Park at the Danforth Plant Science Center in St. Louis, Missouri, Akermin operates at the intersection of biotechnology and industrial sustainability. The company specializes in the development of advanced biocatalytic solutions designed to optimize conventional industrial processes. Its core innovation, a proprietary Biocatalyst Delivery System, integrates enzymes to facilitate energy-efficient, green CO2 management. This technology addresses critical market demands for carbon mitigation, offering scalable alternatives to traditional, energy-intensive industrial practices. By embedding its enzymatic solutions directly into existing workflows, Akermin provides a seamless pathway for heavy industry to reduce its environmental footprint while maintaining operational efficiency.
How much funding has Akermin raised?
Akermin has raised a total of $12.6M across 4 funding rounds:
Unspecified
$600K
Unspecified
$6.1M
Unspecified
$4.1M
Debt
$1.8M
Unspecified (2009): $600K, investors not publicly disclosed
Unspecified (2009): $6.1M, investors not publicly disclosed
Unspecified (2010): $4.1M, investors not publicly disclosed
Debt (2013): $1.8M, investors not publicly disclosed
Key Investors in Akermin
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Akermin?
With the recent influx of capital, Akermin is expected to prioritize the commercialization of its CO2 management platform. The strategic roadmap likely involves scaling its Biocatalyst Delivery System for broader industrial application, moving beyond pilot programs to full-scale integration. As the global regulatory environment increasingly mandates carbon reduction, Akermin's focus on enzymatic efficiency positions it as a key player in the green technology sector. Future growth will likely be driven by strategic partnerships with industrial manufacturers seeking to decarbonize their supply chains, alongside continued investment in R&D to refine the performance and durability of its biocatalytic agents in diverse, high-stress industrial environments.
See full Akermin company page
